Please assess the completion status of the following clinical trial:

Trial Title: Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age at least 18 years~2. Ability and willingness of participant or Legally Authorized Representative (LAR) to give written informed consent.~3. Laboratory confirmed diagnosis of infection with SARS-CoV-2 by PCR~4. Hospitalized for COVID-19 with one or more respiratory or gastrointestinal (GI) symptoms:~   * COVID-19 associated respiratory symptoms include but are not limited to: cough, shortness of breath, difficulty breathing, or sore throat~  * COVID-19 associated GI symptoms include but are not limited to: loss of taste, loss of sense of smell, diarrhea, nausea, or vomiting,~Note: Respiratory and GI symptoms other than those listed above, must be noted as acceptable and signed by study PI or designee.~Exclusion Criteria:~1. Receipt of pooled immunoglobulin in past 30 days~2. Current or prior enrollment in a SARS-CoV-2 antibody or T-cell therapeutic study.~   Note: Patients enrolled on other randomized controlled trials of pharmaceutical and/or non-pharmaceutical interventions for COVID and meeting eligibility criteria will not be excluded, as determined by study PI (or designee) on a case-by-case basis and as allowed by eligibility criteria of the other trials.~3. Contraindication to transfusion or history of prior reactions to transfusion blood products. This may include religious or cultural objections to receiving blood products and transfusions.~4. ABO-compatible titered plasma is not available~5. \> 10 days from noted COVID-related subjective or objective fever at randomization. Patients without subjective or objective fever, \> 10 days from symptom onset as determined by study PI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- High-Titer (CCP1) (Type: EXPERIMENTAL): Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive high-titer ABO-compatible convalescent COVID-19 plasma (CCP1) within 24 hours following random assignment.
- Standard-Titer (CCP2) (Type: ACTIVE_COMPARATOR): Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive standard-titer ABO-compatible convalescent COVID-19 plasma (CCP2) within 24 hours following random assignment.

Based on this trial design, predict the completion outcome and termination type (if applicable).